On Wednesday, Stryker received a positive adjustment to its Relative Strength (RS) Rating, from 68 to 71.
Can You Really Time The Stock Market?
This unique rating measures technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the market's biggest winners often have an RS Rating of above 80 in the early stages of their moves. See if Stryker can continue to show renewed price strength and clear that threshold.
Stryker is trying to complete a consolidation with a 406.19 buy point. See if the stock can break out in volume at least 40% higher than normal.
Earnings-per-share growth dropped in the company's latest report from 16% to 14%, but revenue rose from 11% to 12%. Keep an eye out for the company's next round of numbers on or around Jul. 31.
The company holds the No. 6 rank among its peers in the Medical-Products industry group. Boston Scientific, Insulet and ResMed are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
